|
Irinotecan (drug) Clinical Trials
4 actively recruiting trials across 1 location
▲ +1 trial since June 2026
Also known as: CPT-11
Pipeline
Phase 2: 1Phase 1/2: 3
Top Sponsors
- University of Birmingham1
- Sun Yat-sen University1
- Phanes Therapeutics1
- Australian & New Zealand Children's Haematology/Oncology Group1
Indications
- Cancer4
- Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)1
- Neuroendocrine Prostate Cancer (NEPC)1
- Large Cell Neuroendocrine Cancer (LCNEC)1
- Neuroendocrine Carcinomas (NEC)1
Other3 trials
Duarte, California1 trial
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.